|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Respiratory Division of Federal University of São Paulo, Brazil
2 From the Endocrinology Division of Federal University of São Paulo, Brazil
3 From the Division of Respiratory Medicine, University of Toronto, Canada
Study objective: To evaluate the influence of oral anabolic steroids on body mass index (BMI), lean body mass, anthropometric measures, respiratory muscle strength, and functional exercise capacity among subjects with COPD.
Design: Prospective, randomized, controlled, double-blind study.
Setting: Pulmonary rehabilitation program.
Participants: Twenty-three undernourished male COPD patients in whom BMI was below 20 kg/m2 and the maximal inspiratory pressure (PImax) was below 60% of the predicted value.
Intervention: The study group received 250 mg of testosterone IM at baseline and 12 mg of oral stanozolol a day for 27 weeks, during which time the control group received placebo. Both groups participated in inspiratory muscle exercises during weeks 9 to 27 and cycle ergometer exercises during weeks 18 to 27.
Measurements and results: Seventeen of 23 subjects completed the study. Weight increased in nine of 10 subjects who received anabolic steroids (mean, +1.8±0.5 kg; p<0.05), whereas the control group lost weight (
0.4±0.2 kg). The study group's increase in BMI differed significantly from that of the control group from weeks 3 to 27 (p<0.05). Lean body mass increased in the study group at weeks 9 and 18 (p<0.05). Arm muscle circumference and thigh circumference also differed between groups (p<0.05). Changes in PImax (study group, 41%; control group, 20%) were not statistically significant. No changes in the 6-min walk distance or in maximal exercise capacity were identified in either group.
Conclusion: The administration of oral anabolic steroids for 27 weeks to malnourished male subjects with COPD was free of clinical or biochemical side effects. It was associated with increases in BMI, lean body mass, and anthropometric measures of arm and thigh circumference, with no significant changes in endurance exercise capacity.
Key Words: anabolic steroids body mass index chronic obstructive pulmonary disease nutrition respiratory muscle function
Submitted on June 25, 1997
Accepted on February 11, 1998
This article has been cited by other articles:
![]() |
A. L. Ries, G. S. Bauldoff, B. W. Carlin, R. Casaburi, C. F. Emery, D. A. Mahler, B. Make, C. L. Rochester, R. ZuWallack, and C. Herrerias Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines Chest, May 1, 2007; 131(5_suppl): 4S - 42S. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Marqueti, N. A. Parizotto, R. S. Chriguer, S. E. A. Perez, and H. S. Selistre-de-Araujo Androgenic-Anabolic Steroids Associated With Mechanical Loading Inhibit Matrix Metallopeptidase Activity and Affect the Remodeling of the Achilles Tendon in Rats Am. J. Sports Med., August 1, 2006; 34(8): 1274 - 1280. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Malkin, P. J. Pugh, J. N. West, E. J.R. van Beek, T. H. Jones, and K. S. Channer Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial Eur. Heart J., January 1, 2006; 27(1): 57 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Laghi Low Testosterone in Chronic Obstructive Pulmonary Disease: Does It Really Matter? Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1069 - 1070. [Full Text] [PDF] |
||||
![]() |
T. Troosters, R. Casaburi, R. Gosselink, and M. Decramer Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 19 - 38. [Full Text] [PDF] |
||||
![]() |
F. Laghi, W. E. Langbein, A. Antonescu-Turcu, A. Jubran, C. Bammert, and M. J. Tobin Respiratory and Skeletal Muscles in Hypogonadal Men with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 598 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Casaburi, S. Bhasin, L. Cosentino, J. Porszasz, A. Somfay, M. I. Lewis, M. Fournier, and T. W. Storer Effects of Testosterone and Resistance Training in Men with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 870 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Mador, E. Bozkanat, A. Aggarwal, M. Shaffer, and T. J. Kufel Endurance and Strength Training in Patients With COPD Chest, June 1, 2004; 125(6): 2036 - 2045. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.C. Creutzberg and R. Casaburi Endocrinological disturbances in chronic obstructive pulmonary disease Eur. Respir. J., November 2, 2003; 22(46_suppl): 76S - 80s. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. L. Crawford, P. Y. Liu, M. T. Kean, J. F. Bleasel, and D. J. Handelsman Randomized Placebo-Controlled Trial of Androgen Effects on Muscle and Bone in Men Requiring Long-Term Systemic Glucocorticoid Treatment J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3167 - 3176. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. G. Boyce Use and Effectiveness of Performance-Enhancing Substances Journal of Pharmacy Practice, February 1, 2003; 16(1): 22 - 36. [Abstract] [PDF] |
||||
![]() |
M. J. Mador Muscle Mass, Not Body Weight, Predicts Outcome in Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., September 15, 2002; 166(6): 787 - 789. [Full Text] |
||||
![]() |
M. I. Polkey Muscle Metabolism and Exercise Tolerance in COPD* Chest, May 1, 2002; 121(5_suppl): 131S - 135S. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Weisberg, J. Wanger, J. Olson, B. Streit, C. Fogarty, T. Martin, and R. Casaburi Megestrol Acetate Stimulates Weight Gain and Ventilation in Underweight COPD Patients* Chest, April 1, 2002; 121(4): 1070 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Basaria, J. T. Wahlstrom, and A. S. Dobs Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5108 - 5117. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Akner and T. Cederholm Treatment of protein-energy malnutrition in chronic nonmalignant disorders Am. J. Clinical Nutrition, July 1, 2001; 74(1): 6 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Ferreira, D. Brooks, Y. Lacasse, and R. S. Goldstein Nutritional Intervention in COPD : A Systematic Overview Chest, February 1, 2001; 119(2): 353 - 363. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Kotler Cachexia Ann Intern Med, October 17, 2000; 133(8): 622 - 634. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R Gosker, E. F. Wouters, G. J van der Vusse, and A. M. Schols Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives Am. J. Clinical Nutrition, May 1, 2000; 71(5): 1033 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Casaburi Skeletal Muscle Function in COPD Chest, May 1, 2000; 117(5_suppl_1): 267S - 271S. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Ferreira, D. Brooks, Y. Lacasse, and R. S. Goldstein Nutritional Support for Individuals With COPD: A Meta-analysis Chest, March 1, 2000; 117(3): 672 - 678. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Dobs Is There a Role for Androgenic Anabolic Steroids in Medical Practice? JAMA, April 14, 1999; 281(14): 1326 - 1327. [Full Text] [PDF] |
||||
![]() |
Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease . A Statement of the American Thoracic Society and European Respiratory Society Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): S2 - 40. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |